Navigation Links
Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
Date:2/6/2008

NEW BRUNSWICK, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today the results of preclinical animal studies focused on multiple myeloma that were conducted concurrently at Mayo Clinic and the University of Waterloo. The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco's Factor 5A technology to induce apoptosis in tumors. Additionally, the studies evaluated the efficacy of nanoparticles as a vehicle for encapsulation and delivery of Factor 5A to tumors.

SCID (severe combined immunodeficiency) mice were injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were injected intratumorally with Factor 5A therapy encapsulated in nanoparticles, while control mice received a nanoparticle without the Factor 5A therapy. One of the dosing regimens showed evidence of significant tumor regression relative to the untreated control mice, while the other showed a diminished rate of tumor growth along with some regression.

The Company believes that the results of this study, together with the results of previous studies may be sufficient to plan the preclinical toxicology studies to support an Investigational New Drug Application at the Food and Drug Administration.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene- regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5683

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
2. Guava Technologies Celebrates Tenth Anniversary
3. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
4. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
5. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
6. Neurobiological Technologies Sets Date for Second Quarter Financial Results
7. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
8. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
9. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
10. Genelabs Technologies, Inc. Announces Resignation of President and CEO
11. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):